AstraZeneca gets $107 mln Pfizer verdict overturned in US cancer drug patent fight

On Wednesday, U.S. District Judge Matthew Kennelly invalidated Pfizer’s patents related to the cancer drug Nerlynx, overturning a jury's $107.5 million award against AstraZeneca. Pfizer had claimed AstraZeneca's Tagrisso infringed these patents. Judge Kennelly's ruling found the patents lacked sufficient written descriptions and were not reproducible by a skilled scientist. This decision dismisses the damages awarded in May and affects Pfizer’s ongoing patent infringement claims. The case, Wyeth LLC v. AstraZeneca Pharmaceuticals LP, was heard in the District of Delaware.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bQkDPxv
via IFTTT

Read More

Aurobindo may take its injectable unit public

Aurobindo Pharma is revisiting plans to sell a strategic stake in its injectable unit, Eugia Pharma Specialities, focusing on an IPO. Previously hampered by valuation issues with private equity, the process faces new hurdles due to USFDA observations. Eugia aims to reach $600 million in revenue this fiscal year. Regulatory issues at Unit-3 remain a concern.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NEiOlVA
via IFTTT

Read More

Nishkala Healthcare acquires Navi Mumbai's Suasth Hospital under IBC process

Nishkala Healthcare acquired Suasth Healthcare Foundation's 400-bed hospital in Navi Mumbai for Rs 189 crore under IBC. Funded through Rs 73 crore in equity and bank loans, the purchase follows the hospital's admission into insolvency. Nishkala aims to enhance the hospital’s value and expand into medical education.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JZlsSpE
via IFTTT

Read More

Alembic gets USFDA nod for generic medication

Alembic Pharmaceuticals announced approval from the USFDA to market Dabigatran Etexilate Capsules (110 mg) for deep vein thrombosis prophylaxis, equivalent to Pradaxa Capsules. The company now has 211 ANDA approvals. Shares closed 3.17% lower at Rs 1,076 on the BSE.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ugt7MJ5
via IFTTT

Read More

Southern states witness majority heart transplants owing to more donations

Southern states in India lead in heart transplantation as per Notto data. Tamil Nadu topped the list at 70 transplants, followed by Karnataka, Maharashtra, Gujarat, and Telangana. South India receives more heart donations due to increased deceased donations. India recorded 1,099 heart donations in 2023, with Telangana leading at 252, followed by Tamil Nadu and Karnataka. Dr YK Misra noted the importance of deceased donors for heart transplants. He highlighted the need for amendments to organ transplant laws in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TaM8EzU
via IFTTT

Read More

Biocon arm's growth formula: US rollouts & debt reduction

Biocon Biologics planned to introduce six new biosimilar products in the US in the next two years, subject to regulatory approval. They emphasized debt reduction and cost optimization, having paid $175 million out of $335 million for a key acquisition. Their revenue increased 3% in Q1FY25 due to gains in the biosimilars market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ModbxCQ
via IFTTT

Read More

SSUHS signs MoU with Novo Nordisk Foundation

Srimanta Sankaradeva University of Health Sciences and Novo Nordisk Foundation signed an MoU to enhance Assam's health sector. The deal aims to improve nursing education, including an Education Innovation Unit and Simulation Lab. The partnership provides initial financial support of Rs 6 crore and promises further collaboration to improve nursing education and development.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oOHmLUy
via IFTTT

Read More